Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    17404082 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: Alisertib;   Drug: Abiraterone acetate;   Drug: Prednisone
2 Unknown  Prognostic Value of the Levels of CTCs in Peripheral Blood in Patients With Prostate Cancer at High Risk (Clinical Stages IIB-III) Treated Radically With Radiotherapy and Hormone Therapy.
Condition: Patients With High-risk Prostate Cancer
Intervention:

Study has passed its completion date and status has not been verified in more than two years.